CQ Researcher provides award winning in-depth coverage of the most important issues of the day. Our reports are written by experienced journalists, footnoted and professionally fact-checked. Full-length articles include an overview, historical background, chronology, pro/con feature, plus resources for additional research. Graphics, photos and short "sidebar" features round out the reports. Shorter "Hot Topics" articles provide a solid introduction to subjects most in demand by students.
Recent high-profile Senate hearings have highlighted a phenomenon many Americans know well: the soaring price of prescription drugs, some needed to keep patients alive. New blockbusters routinely cost more than $100,000 for a course of treatment, and similar “me too” drugs for the same conditions later launch at almost identical prices. Drug manufacturers blame the rising cost of research and development, but critics blame excessive profit-seeking and exorbitant marketing budgets. Meanwhile, prices for some common, decades-old generics also are rising as competition in that part of the industry collapses. The price of the antibiotic tetracycline, for example, rose more than 7,500 percent in two years. A majority of Americans say keeping drug prices affordable should be the top national health care priority, and all three remaining presidential candidates have promised relief. To help slow the rising costs, states are introducing bills and ballot measures to require drug makers to disclose their actual costs and, in some cases, cap prices.
At least 11 states are considering bills to raise pricing disclosure requirements.
Makers of expensive hepatitis C treatments face scrutiny over pricing.
Democratic House members seek to withdraw companies’ marketing rights to unreasonably priced drugs.
|1850s–1905||The heyday of patent medicines ushers in widespread, unregulated advertising.|
|1906–1959||Congress regulates drugs and investigates drug companies' wrongdoing.|
|1980–1984||Biotechnology revolution and other innovations send new-drug prices higher.|
|1987–Present||High and sharply rising drug prices prompt calls for reform.|
Should Medicare be allowed to negotiate drug prices?
Senior Fellow and Director of Health Policy Research, Political Economy Research Institute, University of Massachusetts, Amherst; and. Professor of Law, Cleveland State University.
President, American Action Forum; Former Director, Congressional Budget Office.